Niagen Bioscience (NAGE) said Thursday that it has received a US patent for composition of matter for nicotinamide riboside salt forms, expanding its nicotinamide adenine dinucleotide precursor intellectual property portfolio.
The company said it owns and licenses a portfolio of more than 90 patents related to its nicotinamide riboside ingredient Niagen.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.